// App-Quantinova.ai

CTIM-14 : PELAREOREP AND GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF) WITH STANDARD CHEMORADIOTHERAPY/ADJUVANT TEMOZOLOMIDE FOR GLIOBLASTOMA MULTIFORME (GBM) PATIENTS: REOGLIO PHASE I TRIAL RESULTS

Researchers

Presenter

  • Jessica Kendall

Principal Investigators

  • Anthony Chalmers

  • Catherine McBain

  • Alan Melcher

  • Adel Samson

  • Rachel Phillip

  • Sarah Brown

  • Susan Short

Medical Centers

  • University of Leeds, Leeds, United Kingdom

  • University of Glasgow, Glasgow, United Kingdom

  • The Christie NHS Foundation TRUST, Manchester, United Kingdom

  • Institute of Cancer ResearchRoyal Marsden National Institute for Health Research Biomedical Research Centre, London, United Kingdom

  • Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Glioblastoma

Biomarkers

  • Granulocyte-macrophage-colony stimulating factor

Drug/Treatment

  • Temozolomide

  • Pelareorep

  • GM-CSF

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved